Agios Pharmaceuticals to Present at Major Healthcare Conference
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), recognized for its significant contributions to cellular metabolism and PK activation, has announced its upcoming participation in a major healthcare event. The presentation is set for the esteemed 2024 Cantor Global Healthcare Conference, taking place in the morning. This event will showcase Agios's dedication to developing innovative therapies for rare diseases.
Event Details
Agios is scheduled for a mid-morning presentation, where they will discuss their cutting-edge approaches and recent clinical advancements. Those interested can watch the live webcast, which is usually available in the Investors section of the company's official website. After the event, a recorded version of the presentation will be accessible on Agios's website for a limited time.
About Agios Pharmaceuticals
Agios is a leader in PK activation, focusing on creating transformative therapies for patients with rare conditions. The company has successfully launched a groundbreaking pyruvate kinase (PK) activator in the U.S., marking it as the first disease-modifying therapy aimed at helping adults with PK deficiency, a serious and chronic hemolytic anemia.
Research and Development Focus
Beyond their marketed therapies, Agios has a strong pipeline of clinical trials that are exploring treatments for various conditions, including alpha- and beta-thalassemia, sickle cell disease, and pediatric PK deficiency. They are also investigating innovative therapies for MDS-associated anemia and phenylketonuria (PKU), demonstrating their commitment to meeting diverse medical needs.
Upcoming Innovations
Additionally, Agios is progressing with a potential preclinical treatment for polycythemia vera, highlighting its commitment to advancing the treatment landscape for rare diseases. Their drug development initiatives are supported by a profound understanding of classical hematology and a leadership position in cellular metabolism.
Company Contacts
Investors seeking more information can reach out to Agios's designated contacts. Chris Taylor, the Vice President of Investor Relations and Corporate Communications, is available for inquiries at IR@agios.com. For media-related questions, Dan Budwick at 1AB can provide further engagement regarding Agios's initiatives.
Frequently Asked Questions
What is Agios Pharmaceuticals known for?
Agios Pharmaceuticals focuses on developing therapies for rare diseases, leveraging its expertise in cellular metabolism and PK activation.
When will Agios present at the Cantor Conference?
The presentation is scheduled for a morning slot during the 2024 Cantor Global Healthcare Conference.
How can I access the live presentation?
You can access the live presentation through the Investors section of the Agios official website, where updates will be posted.
What therapies has Agios brought to market?
Agios has successfully launched a first-in-class pyruvate kinase activator for adults with PK deficiency.
Who can I contact for more information about Agios?
For investor inquiries, you can contact Chris Taylor, and for media inquiries, reach out to Dan Budwick.